张䶮, 范延红, 孙冬冬. 沙库巴曲缬沙坦治疗心力衰竭的研究进展[J]. 心脏杂志, 2020, 32(2): 193-196. DOI: 10.12125/j.chj.201911053
    引用本文: 张䶮, 范延红, 孙冬冬. 沙库巴曲缬沙坦治疗心力衰竭的研究进展[J]. 心脏杂志, 2020, 32(2): 193-196. DOI: 10.12125/j.chj.201911053
    Yan ZHANG, Yan-hong FAN, Dong-dong SUN. Research progress of sacubitril/valsartan in heart failure[J]. Chinese Heart Journal, 2020, 32(2): 193-196. DOI: 10.12125/j.chj.201911053
    Citation: Yan ZHANG, Yan-hong FAN, Dong-dong SUN. Research progress of sacubitril/valsartan in heart failure[J]. Chinese Heart Journal, 2020, 32(2): 193-196. DOI: 10.12125/j.chj.201911053

    沙库巴曲缬沙坦治疗心力衰竭的研究进展

    Research progress of sacubitril/valsartan in heart failure

    • 摘要: 沙库巴曲缬沙坦是全球近年来慢性心力衰竭(HF)治疗领域具有突破性的创新药物,它是一种血管紧张素受体-脑啡肽酶抑制剂,可同时抑制肾素-血管紧张素-醛固酮系统并调节利钠肽系统。已被证实为目前首个也是唯一一个较标准治疗显著改善HF患者预后的药物,较依那普利能够显著改善射血分数,降低HF患者的死亡风险及再入院率,目前已被各国HF治疗指南推荐为慢性HF的一线治疗药物。后续更多研究表明,沙库巴曲缬沙坦还有逆转心脏重构、保护肾功能、降低血糖等作用,临床应用范围更加广泛,是应该大力推广的抗HF药物。本文将对沙库巴曲缬沙坦治疗HF的最新研究进展做一综述。

       

      Abstract: As an innovative drug in the field of chronic heart failure treatment worldwide in recent years, sacubitril-valsartan is a combination drug that contains the neprilysin inhibitor sacubitril and angiotensin receptor blocker valsartan. In the PARADIGM-HF trial, sacubitril/valsartan significantly reduced the primary endpoint of cardiovascular mortality and heart failure hospitalization, compared with enalapril. The rate of all-cause mortality was also significantly reduced. Subsequently, the European Society of Cardiology and American College of Cardiology/American Heart Association/Heart Failure Society of America recently have updated guideline recommendations for heart failure with reduced ejection fraction to recommend sacubitril/valsartan. This manuscript reviews new research of sacubitril/valsartan in heart failure.

       

    /

    返回文章
    返回